[Development of effective antigen delivery carrier to dendritic cells via Fc receptor in cancer immunotherapy].
In cancer immunotherapy with dendritic cells (DCs), which are the most potent antigen-presenting cells, it is important that DCs present peptides derived from tumor-associated antigens on major histocompatibility complex (MHC) class I molecules and activate tumor-specific cytotoxic T lymphocytes. However, exogenous antigens are generally presented on MHC class II but not class I molecules. To develop effective immunotherapy for cancer, an antigen delivery carrier that can induce MHC class I presentation of exogenous antigens is necessary. Several strategies to induce DCs to present exogenous antigens on MHC class I molecules have been reported. First, DCs that phagocytosed a particulate form of antigens present peptides derived from the antigens on MHC class I molecules. Second, DCs that incorporated antigens via certain endocytic receptors such as Fc receptors efficiently present peptides on MHC class I molecules. We combined these two strategies and prepared antigen-containing IgG-conjugated liposomes (IgG-liposomes). In this study, we investigated the feasibility of IgG-liposomes as antigen delivery carriers in cancer immunotherapy with DCs. Immunization of mice with DCs that endocytosed ovalbumin (OVA)-containing IgG-liposomes, but not OVA-containing bare liposomes or soluble OVA, completely prevented the growth of OVA-expressing lymphoma cells. These results suggest that IgG-liposomes represent an efficient antigen delivery carrier for DCs in cancer immunotherapy.
Suzuki
Ryo
R
Department of Biopharmaceutics, School of Pharmaceutical Sciences, Teikyo University, Sagamiko-cho, Sagamihara City, Japan. r-suzuki@pharm.teikyo-u.ac.jp
Utoguchi
Naoki
N
Kawamura
Kazuko
K
Kadowaki
Norimitsu
N
Okada
Naoki
N
Takizawa
Tomoko
T
Uchiyama
Takashi
T
Maruyama
Kazuo
K
D000818:Animals; D017951:Antigen Presentation / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology*; D016503:Drug Delivery Systems; D004705:Endocytosis; D006801:Humans; D007074:Immunoglobulin G; D007167:Immunotherapy; D008081:Liposomes; D051379:Mice; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D011961:Receptors, Fc / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D007074:Immunoglobulin G; D008081:Liposomes; D011961:Receptors, Fc